NCT07487389

Zilganersen Expanded Access Program for Individuals With Alexander Disease

• Status: Available
• Phase: —
• Study type: Expanded Access
• Enrollment: —
• Sponsor: Ionis Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 2 Years – 99 Years
• Healthy volunteers: —

Summary

The purpose of the expanded access program (EAP) is to provide access to zilganersen for eligible individuals with Alexander disease (AxD).

Detailed description

This is an expanded access program (EAP) for eligible individuals diagnosed with Alexander disease residing in the United States, prior to approval of zilganersen by the local regulatory agency (FDA). A medical doctor must decide whether the potential benefits of zilganersen outweigh the potential risks based on the individual patient's medical history and program eligibility criteria. Access can be requested via the contact information below.

Conditions

• Alexander Disease

Interventions

Type	Name	Description
DRUG	zilganersen	zilganersen

Timeline

• First posted: 2026-03-23
• Last updated: 2026-03-23